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ESSAY
Blockchain’s potential to improve clinical trials—an
essay by Leeza Osipenko
There’s more to this tamperproof technology than bitcoin. It could be used to improve the
administration of clinical trials, ensuring transparency and yielding better quality data, writes Leeza
Osipenko
Leeza Osipenko senior lecturer in practice, London School of Economics and Political Science, and
visiting fellow, Center for Global Development
London
Blockchain is the digital technology that underpins
cryptocurrencies such as bitcoin (box 1). In essence it uses
cryptography to guarantee that multiple sets of the same data,
held by separate users, are identical.
Box 1: What are blockchains and smart contracts?
Blockchain is a way of managing data that prevents their manipulation.1 A
new “block” of data records each specific event. Each block is time stamped
and includes cryptographic information (a “hash”) from the previous block.
These hashes link blocks securely to form chains, making data modification
impossible without changing the entire chain.
All users in a network have their own copy of the blockchain. This
decentralisation of data enables transparency and further security, because
any modification has to be sanctioned by all users.1 Current, centralised ways
of managing data lack such assurance.
Blockchain cannot protect from errors when data are entered, but it can ensure
the provenance of data and improve transparency. Erasing blockchain data
is impossible, so data can be updated or modified only by adding new blocks,
and any obsolete blocks will remain.
Smart contracts are versatile computer algorithms mandating that all users
follow prespecified rules for a given task,1 without the need for centralised
supervision or inspection. For example, smart contracts could replace many
activities in auditing clinical trials. Currently, auditors ensure that specific
documents are in order before an investigator can begin a trial. A smart
contract could be coded to mandate that patient enrolment cannot begin before
all documents are uploaded.
Blockchain’s underlying technical features make no difference to users, who
interact with a conventional web based interface for entering and retrieving
data.
Blockchain’s applications in finance have given it a questionable
reputation because many hyped cryptocurrency projects have
failed. But blockchain has some features that could, if applied
well, improve the quality of clinical research.
Data from clinical trials belong to a sponsor, an academic, or a
charity. Even data from publicly funded research are not public
property, and accountability for transparency and impartiality
can be lacking. Most patients and their carers never find out
how trial participation informs clinical practice or further
research.
Clinical trials are prone to research misconduct, data
falsification, or simply unintended errors.2-4 Trials often deviate
from prespecified protocol or may record inaccurate case
histories.5 The extent of these problems is difficult to quantify,3
but—along with inappropriate trial design and data analysis,
under-reporting of results, and publication bias—it leads to
significant waste in clinical research.6 7 Legislative, cultural,
and practical solutions are needed.
Blockchain offers a technical solution that could eradicate data
manipulation, improving the transparency, security, quality,
and efficiency of clinical trials as well as the auditing of data
and processes.
Running trials using blockchain
Today’s centralised data processing and storage systems cannot
ensure data security and integrity. Servers can be hacked, and
data can be corrupted. Users with access to databases can tamper
with data, and it may not be possible to find out who changed
records and when. Blockchain could solve these problems.
Blockchains can be public or private. Because clinical trials
concern sensitive information they would use a private
blockchain network including all parties who are conducting,
auditing, analysing, and assessing the trial. Data would be visible
only to participating regulators, academics, independent
assessors, sponsors, and funders.
The smart contracts that blockchain facilitates could also
improve quality control and trial efficiency (box 1). These
algorithms could replace some functions of third parties such
as auditors and contract research organisations by verifying data
or confirming that particular actions have occurred.
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Smart contracts can be configured to streamline complicated
processes. For example, they could mandate that users enter
data on the blockchain according to a prespecified sequence of
events. This could reduce missing data and improve trial quality.
A smart contract could dictate, for example, that an investigator
must log a record of a patient’s outcome, or a patient’s absence,
on day 28. If this does not happen the system could alert all
users in the network and require data entry before the next step
(say, the entry of outcome measures on day 56).
Could it work?
Blockchain is already used successfully in supply chain logistics,
entertainment, insurance, and other applications8—but not in
clinical trials. The drug and medical device industry may lack
interest because blockchain is unlikely to translate into profits.
And public sector organisations are notoriously slow to adopt
new technology, even though regulators and funders mandate
integrity and transparency of trial data. As a result, blockchain’s
potential in clinical trials remains theoretical, but proofs of
concept exist.
Wong and colleagues developed a blockchain prototype for a
completed trial of omalizumab. They showed how the
technology could have been used in trial governance and data
management.9 A simulated corruption of a trial record showed
how easily data on blockchain can be checked for tampering
without having to inspect each file. The work showed how
cryptographic labels attached to transaction records can ensure
security of data.
In a similar approach, Nugent and colleagues used modelled
data representing trials of oseltamivir to show how blockchain
can eliminate data manipulation and provide an immutable
record of a trial’s history.10 They also showed how the state of
the data can be queried to show the number of trials under way,
the number of participants recruited to each trial, and the user
making each transaction, resolvable to a specific contract
research organisation. Current systems, even those that allow
such detailed inquiries, cannot guarantee the provenance of data.
Another proof of concept study used a blockchain system to
collect participants’ consent for inclusion in a trial. Benchoufi
and colleagues piloted smart contracts to mandate a
pre-programmed order for trial events: for example, patients
had to be enrolled before they gave consent, and case report
forms had to be analysed before freezing the database on
completion of the study.11
Events and outcomes
Blockchain could also improve other aspects of clinical trials,
including adverse event reporting and endpoint adjudication.
Regulators require drug trial sponsors to report any serious
adverse events. But inefficient processes involve several steps,
and many problems are cited by academia, industry, and contract
research organisations,2 including the bureaucratic burden and
poor quality reporting. Blockchain with smart contracts could
ensure that only reports meeting set criteria are submitted (such
as specified by US federal regulations). This could decrease the
number of uninformative reports and improve detection of valid
safety signals. Using blockchain, reports could go directly to
the regulator, without a contract research organisation
intermediary.9
Incorrect classification of trial outcomes can reduce power and
lead to biased estimates of a treatment effect.12 Endpoint
adjudication should be performed throughout trials. Once an
investigator uploads a scan, an endoscopic video, or a clinical
summary, a smart contract could ensure that it is sent to
prespecified independent experts in the blockchain network to
obtain their conclusions. For complex endpoints a review of
many data sources (such as investigator reports, safety
summaries, local and central laboratory data, hospital attendance
records, and case reports) may be required to establish that the
event has occurred.13 The smart contract could include quality
assurance to require that the investigator and independent
assessors follow the same steps to detect the event or to
determine that an endpoint has been reached.
A blockchain network could mandate many features of universal
good clinical practice in processes and forms without third party
audit. Smart contracts could allow auditing of each step in a
trial according to protocol or other requirements. Regulators
could be automatically alerted about non-compliance. Such
advances could increase quality control, improving reliability,
transparency, and reproducibility.11 Eventually, observational
studies, registries, genomic studies, and so on could also be
managed using blockchain.
Embracing integrity in clinical research
Blockchain would be unable to improve many of the weaknesses
in clinical trials (box 2), but its impact would be maximised if
implemented with other reforms. Regulators, funders, and policy
makers must challenge the status quo in clinical research. All
trial protocols, including detailed plans for data analysis, should
be pre-registered, peer or regulator reviewed, and published
online before the trial starts. Deviations from protocol should
be documented and explained in full. Data should be analysed
in parallel by the sponsor and by independent groups, using
clearly reported and replicable methods and according to
prespecified hypotheses. Results should be factually reported,
to minimise publication and interpretation bias.
Box 2: Blockchain’s potential for clinical trials
Blockchain could:
• Improve data quality and completeness
• Prevent data tampering
• Ensure proper per protocol trial execution and governance
• Prevent endpoint switching
• Enable efficient information sharing (such as adverse event reporting,
patient consent, or conflicts of interest)
• Improve integrity of outcomes data evaluation (endpoint adjudication),
and
• Deliver the complete dataset to each stakeholder for parallel analysis.
Blockchain cannot:
• Advance the quality, rigour, and rationality of trial design
• Alleviate poor use of methods for data analysis
• Avoid hypothesising after the results are known
• Resolve methodological issues in endpoint adjudication
• Prevent data entry errors
• Ensure timely reporting of results, or
• Change stakeholder incentives.
Unfortunately, substantial incentives not to increase transparency
and data integrity in medical research persist. Industry believes
in data ownership and confidentiality because its proprietary
analyses and strategic releases of data regulate share prices.
Many academics receiving public funds feel entitled to own and
analyse the data from their research. But overwhelming evidence
of bias exists when commercial or academic investigators
analyse and report their own findings.3 4 6
Today, data provenance and integrity cannot be assured even
by allocating analysis to third parties. Blockchain could deliver
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assured datasets to independent parties for analysis. This would
separate the merit of doing a trial from its results and would
allow researchers to focus on ideas and methods. In analyses
that include more than a single trial or contain data from other
sources, blockchain could make data compilation simpler.9 In
these collaborative initiatives the anonymised raw data could
be shared, and blockchain would provide reassurance that
records had not been tampered with.
Control of implementation
“Blockchain” has become a buzzword. Some entrepreneurs and
researchers evangelise its promise of innovation, but others are
turned off by the hype surrounding the technology. Blockchain
sceptics warn about high costs. Indeed, when used with
cryptocurrencies, blockchain deliberately uses resource intensive
calculations to mint new currency. But blockchain solutions for
clinical trials9 do not need these slow and costly “mining
functions.”10
Blockchain solutions are evolving rapidly, becoming cheaper
and more versatile. Any new technology can be slow to yield
benefit. Whatever destiny awaits blockchain in clinical research,
its implementation will be subject to technical, financial, and
market driven risks; however, the major impediment is likely
to be sociopolitical.
Policy change is notoriously difficult. In the past 20 years we
have made much progress in increasing the bureaucracy and
complexity of clinical research14 but little in improving its
quality, efficiency, and accountability.6 7 Even when we succeed
in introducing new policies their enforcement has often been
interpreted as optional. Regulators are not collecting fines for
trial non-reporting, for example, and pre-registration of protocols
is still lacking.7 15
Patients taking part in clinical trials deserve every record to be
counted, appropriately handled, and independently assessed.
Increased transparency and data integrity would help to
accomplish this. The remit of regulators and the funders of
non-commercial research is to protect and advance public
health—and therefore they, rather than industry or academia,
should lead blockchain’s implementation in managing clinical
trials.
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